AVP and hydrops fetalis: The Biomarkers in Acute Heart Failure (BACH) trial first suggested that copeptin may offer additional information beyond s-Na and NT-proBNP levels, likely serving as an independent predictor both of 90-day mortality and adverse HF outcomes with additive predictive value (33).